打开APP

Alkermes完成精神分裂症研究里程碑任务

  1. Abilify
  2. Alkermes
  3. 精神分裂症

来源:生物谷 2013-10-11 09:26

2013年10月10日讯 /生物谷BIOON/ --爱尔兰医药公司Alkermes公司完成了其研发的关于精神分裂症长效版本药物Abilify的研究里程碑任务。公司计划将于明年的上半年公布相关的研究数据。研究人员将收集长达12周的研究数据以评估这种药物的有效性。通过与强生公司的合作,Alkermes公司目前已经有了两种精神分裂症药物。此次ALKS3831的研究将为公司在该领域注入新的活力。

2013年10月10日讯 /生物谷BIOON/ --爱尔兰医药公司Alkermes公司完成了其研发的关于精神分裂症长效版本药物Abilify的研究里程碑任务。公司计划将于明年的上半年公布相关的研究数据。研究人员将收集长达12周的研究数据以评估这种药物的有效性。通过与强生公司的合作,Alkermes公司目前已经有了两种精神分裂症药物。此次ALKS3831的研究将为公司在该领域注入新的活力。(生物谷Bioon.com)

详细英文报道:

Ireland's Alkermes ($ALKS) has hit a key milestone in its quest to develop a long-acting version of Abilify for schizophrenia. The biotech, which has R&D operations in Waltham, MA, says it has completed enrollment in the pivotal Phase III study, putting the research team on track to report top-line data in the first half of next year.

"There is a clear and compelling need for long-acting injectable medicines for patients with schizophrenia," said Elliot Ehrich, the chief medical officer of Alkermes. "We are excited to complete enrollment in this carefully conducted, multinational study and look forward to reporting the results in the first half of 2014."

Researchers will gather 12-week data on the change from baseline in the Positive and Negative Syndrome Scale (PANSS) score, a standard outcome measure in the evaluation of schizophrenia treatment.

Alkermes already has a pair of schizophrenia drugs on the market through its marketing deal with J&J. And the biotech has also been prepping a midstage study of an antipsychotic--ALKS 3831--a broad-spectrum therapy combining a new opioid modulator, ALKS 33, and Zyprexa, shooting for a new-and-improved approach to schizophrenia without the threat of sudden weight gain.

Alkermes has been building a solid rep as an experienced developer looking to reformulate and improve on existing therapies.

 

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->